1 / 11

Mhealth

Mhealth. Pharmaceutical Group of European Union. Members: Professional Bodies & Pharmacists ’ Associations . Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Croatia FYR Macedonia Norway Serbia Switzerland Turkey. Austria Belgium

zack
Download Presentation

Mhealth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mhealth

  2. Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists’ Associations Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Croatia FYR Macedonia Norway Serbia Switzerland Turkey Austria Belgium Bulgaria Bosnia Herzegovina Cyprus Czech Rep Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Luxembourg 2014: 32 Countries

  3. Health Apps • IMS study found that just 5 apps account for 15% of market, and two of these are calorie counters; • Half of healthcare apps have only been downloaded 500 times; • The market is overwhelmingly dominated by lifestyle and wellness apps with very few diagnostic or even adherence apps; • There is no evidence [e.g. RCTs] that apps are effective; • There is an inverse relationship between smartphone use and healthcare need. This may change, but not for a long time.

  4. Remote Monitoring

  5. Remote Monitoring • Strong evidence that telemonitoring offers no health benefits over normal care; • Significant problems remain in the area of data transfer and poor adherence – in the NEJM study nearly half trial participants failed to adhere and 14% dropped out immediately; • Chain of Trust study showed that patients and health professionals considered the telehealth agenda to be manufacturer driven.

  6. The Dilemmas of M Health • M Health as a consumer appendage e.g wellness apps is at present a highly marginal phenonemon in terms of overall health service provision, and likely to remain so for the foressable future; • ‘Strong’ M Health (e.g. remote diagnosis and monitoring) needs to break into the mainstream of organised and funded health care. But this is likely to be based on efficiency imperatives, not on patient need, choice or empowerment. • The overall impact of M Health on the technologically incompetent, or averse is unknown, but a case can be made that it will increase health inequalities and undermine social capital.

  7. THANKYOU www.pgeu.eu

More Related